David Scadden

By Anne Manning This article originally appeared in the Harvard Gazette. Many people couldn’t say where their thymus is, or what it does, and even doctors have long considered it expendable in adults. But new Harvard-led research suggests that the walnut...

Bone metastases are devastating developments of cancers that originate in other organs. In the case of metastatic prostate cancer, bone metastases represent an incurable, painful, and often deadly development, killing more than 30,000 American men every...

A group of researchers, led by HSCI Co-Director David Scadden, MD, has shown that bone cells pass packets of genetic material directly to bone progenitors, increasing blood production and stimulating the immune cells necessary to fight infection. Blood is...

HSCI co-director David Scadden is part of a multi-institutional, cross-disciplinary team that has been awarded a $14.6 million grant from the National Institutes of Health. The team is using gene and cell therapy approaches to develop a potential cure for...

Harvard researchers target chemotherapy-resistant leukemia by using metabolism By Jessica Lau Blood cancers like leukemia can be effectively treated with chemotherapy, but relapse usually occurs, due to resistant cancer cells that evade the original drug...

Cancer immunologists and biological engineers at Harvard unite to fight therapy-resistant cancers A new NIH-funded Immuno-Engineering to Improve Immunotherapy (i3) Center at Harvard University sets out to create new anti-cancer immunotherapies using...

Study finds that fatty acids influence skeletal stem cell development When a bone fracture occurs, the stem cells that repair the injury either form new bone or new cartilage. A new study in the journal Nature has identified how this decision happens...

Biomaterial-based vaccine protects against acute myeloid leukemia in mice Acute myeloid leukemia (AML), a blood cancer that originates in the bone marrow has been treated with chemotherapy for over 40 years. While the treatment does often cause the cancer...

New microgel encapsulation method paves the way for more efficient cell therapies Bone marrow transplants have become a standard treatment for a range of blood cancers and diseases, but many transplants fail due to rejection by the patient’s immune system...

The Harvard Stem Cell Institute (HSCI) was launched in 2004 with the express goal of pursuing the promise of stem cell science. In April 2019 we celebrate our 15th anniversary, and reflect on how far we have come. Collaboration across Harvard Our founding...